Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Stopped Study did not meet the predefined primary surrogate efficacy endpoint, no safety issues identified
Conditions
- Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions
- DRUG: Elafibranor
- DRUG: Placebo
Sponsor
Genfit